8-K: ChromaDex Reports Strong Q4 and Full Year 2023 Results, Achieves Profitability Milestone

ChromaDex Corp. announced its fourth quarter and fiscal year 2023 financial results, highlighting a 16% increase in full-year net sales, improved gross margins, and a significant reduction in net loss, achieving profitability in Q4.

Summary

• ChromaDex Corp. reported a 16% increase in full-year net sales for 2023, reaching $83.6 million, compared to $72.1 million in 2022.
• The company achieved a gross margin of 60.8% in 2023, up from 59.4% in the previous year.
• Net loss for 2023 was significantly reduced to $4.9 million, compared to $16.5 million in 2022.
• The company reported a positive Adjusted EBITDA of $1.9 million for 2023, a substantial improvement from a negative $9.97 million in 2022.
• In the fourth quarter of 2023, ChromaDex achieved a net income of $0.1 million, marking a significant milestone for the company.
• Operating cash flows were positive for the fourth consecutive quarter, and the company ended the year with $27.3 million in cash and no debt.
• For 2024, ChromaDex anticipates continued revenue growth, projecting a higher rate than the 16% growth seen in 2023.
• The company plans to increase investments in research and development, as well as general and administrative expenses, to support future growth and innovation.

Sentiment

Score: 8

Explanation: The document reflects a highly positive sentiment due to the company achieving profitability, strong revenue growth, improved margins, and a positive outlook for 2024. The successful execution of strategic initiatives and expansion into new markets further contribute to the positive sentiment.

Positives

• The company achieved positive net income in the fourth quarter of 2023.
• There was a significant reduction in net loss for the full year 2023.
• Gross margin improved both in Q4 and for the full year.
• Selling and marketing expense as a percentage of net sales improved by 770 basis points year-over-year.
• General and administrative expenses decreased by $3.3 million year-over-year.
• The company successfully maintained positive operating cash flows throughout 2023.
• Successful expansion into new markets and partnerships, such as with iHerb and Zesty Paws.

Negatives

• The company still reported a net loss of $4.9 million for the full year 2023.
• Niagen ingredient sales saw a decline of $1.2 million in Q4 2023 compared to the prior year quarter, largely due to a significant upfront purchase from Nestle Health Science in the prior year period.

Risks

• The company has a history of operating losses and may need to obtain additional financing in the future.
• The growth and profitability of product sales may be uncertain.
• Consumer perceptions of the company's products may change.
• The company relies on a single or limited number of third-party suppliers.
• There are risks associated with conducting business in China.
• Inflationary conditions and adverse economic conditions could impact the company's performance.

Future Outlook

For the full year 2024, the company expects the trajectory of revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of 16%. This outlook assumes continued revenue growth through our e-commerce business as well as established partnerships, and assumes upside from opportunities with new partnerships, channels, and products. The company projects that gross margin will improve slightly year-over-year driven by continued supply chain optimization efforts and cost savings, along with overall scale. Moreover, selling and marketing expense will increase in absolute dollars but remain stable as a percentage of net sales, as the company continues to make focused investments to drive brand awareness and support new market launches, while maintaining efficiency. The company plans to increase investments in research and development to drive future innovation and expects an increase in general and administrative expense of $1.5 million $2.5 million to support growth.

Management Comments

• 'ChromaDex had its strongest year yet, achieving $83.6 million in revenue, up 16% year-over-year, with positive adjusted EBITDA of $1.9 million, and consistent positive operating cash flows each quarter. Additionally, the fourth quarter marked an important milestone with the company achieving positive net income,' said Rob Fried, ChromaDex Chief Executive Officer.
• 'Ending the year with $27.3 million in cash and no debt underscores our financial strength. This solid foundation, paired with continued investments in our future, fuels our optimism as we set the stage for accelerated growth in 2024 and beyond. We're confident in our trajectory and excited about the new market opportunities ahead.'

Industry Context

The announcement aligns with the growing interest in healthy aging and NAD+ supplementation. ChromaDex is positioning itself as a leader in the NAD+ market, which is gaining traction due to increasing scientific research highlighting the importance of NAD+ for cellular health and longevity.

Comparison to Industry Standards

• ChromaDex's revenue growth of 16% in 2023 is a strong performance in the nutraceutical industry. For example, Herbalife Nutrition reported a net sales decline of 2.7% in 2023. Similarly, Nature's Sunshine Products reported a net sales decline of 5.9% in 2023.
• ChromaDex's focus on NAD+ precursors, particularly nicotinamide riboside (NR), differentiates it from many competitors in the supplement market. While some companies offer other NAD+ precursors like nicotinamide mononucleotide (NMN), ChromaDex has a strong patent portfolio protecting NR and its use in Tru Niagen.
• ChromaDex's partnerships with retailers like Watsons and its online presence through platforms like Amazon and iHerb are in line with industry trends towards omnichannel distribution. This is similar to the approach taken by companies like GNC and The Vitamin Shoppe, which have both online and physical retail presence.
• The company's investment in research and development, as evidenced by the ChromaDex External Research Program (CERP), is significant. This level of research commitment is seen in larger pharmaceutical and biotechnology companies, but is less common among supplement companies. This positions ChromaDex more closely with research-focused entities in the broader health and wellness sector.

Stakeholder Impact

• Shareholders may benefit from the company's improved financial performance and positive outlook.
• Employees may benefit from the company's growth and investment in research and development.
• Customers will have access to new products like Tru Niagen Pro 1,000 mg and the Healthy Aging NAD+ Precursor supplement for pets.
• Suppliers may benefit from the company's continued growth and demand for ingredients.

Next Steps

• The company will continue to focus on driving Tru Niagen brand awareness.
• Support new market launches with focused investments.
• Increase investments in research and development to drive future innovation.
• Continue supply chain optimization and cost savings initiatives.

Key Dates

Keywords

NAD+, Nicotinamide Riboside, NR, Niagen, Tru Niagen, Healthy Aging, Dietary Supplements, ChromaDex, Metabolic Health, Cellular Health, Clinical Research, Biotechnology, Nutraceuticals